- Record: found
- Abstract: found
- Article: not found
Deal watch: IL-2 focus switches to stimulating Tregs
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Recombinant interleukin-2 (IL-2) has been used since the early 1990s for the treatment of renal cell carcinoma and melanoma, as high-dose IL-2 has immune-stimulating properties. A spate of deals in 2017 — including Eli Lilly's acquisition of co-development rights to Nektar's NKTR-358, the acquisition